openPR Logo
Press release

Respiratory Syncytial Virus(RSV) Therapeutics Market Growth, New Updates, Trends, Analysis and Global Research Report 2021-2026

05-30-2021 07:41 PM CET | Health & Medicine

Press release from: Marketinsightsreports

Respiratory Syncytial Virus(RSV) Therapeutics Market Growth,

The Global Respiratory Syncytial Virus(RSV) Therapeutics Market Report Provides Business Overview, Market Trends, Industry Challenges, And Forecast 2021-2026

The report provides a strategic analysis of the Global Respiratory Syncytial Virus(RSV) Therapeutics Market and the growth estimates for the forecast period 2021 to 2026. The report offers qualitative and quantitative insights and a detailed analysis of market size & growth rate for all possible segments in the market. This report focuses on the major drivers, restraints, opportunities, and threats for key players. Also report focuses on Respiratory Syncytial Virus(RSV) Therapeutics Market Trends, volume, and value at the global level, regional level, and company level.

Get a free sample of this Market report now @ 

https://www.marketinsightsreports.com/reports/05032856998/global-respiratory-syncytial-virus-rsv-therapeutics-market-2021-by-company-regions-type-and-application-forecast-to-2026/inquiry?Mode=G88

The global Respiratory Syncytial Virus(RSV) Therapeutics market size is expected to grow at a CAGR of 5.5% for the next five years.

Top companies operating in the Global Respiratory Syncytial Virus(RSV) Therapeutics market profiled in the report are: Roche, AstraZeneca, Merck, AbbVie, Bausch Health, GlaxoSmithKline, ReViral, Gilead Sciences, Teva Pharmaceutical

Industry News:

AstraZeneca and Sanofi Announce Big Breakthrough With RSV Vaccine[Apr 26, 2021]

Respiratory syncytial virus (RSV) infections cause about 80,000 hospitalizations in children and 500 deaths each year. AstraZeneca and Sanofi announced that their MELODY Phase III trial of nirsevimab hit the primary endpoint in medically attended lower respiratory tract infections (LRTI) caused by RSV in healthy late preterm and term infants.

Nirsevimab is a long-acting antibody designed to act as a passive immunization for the prevention of LRTI caused by RSV. They believe that nirsevimab might only require a single dose during a typical five-month RSV season because of the longer half-life. 

Moderna Announces Updates on Respiratory Syncytial Virus (RSV) Vaccine Program[oct 8, 2020]

(Nasdaq: MRNA) a biotechnology company pioneering messenger RNA

(mRNA) therapeutics and vaccines to create a new generation of transformative

medicines for patients, today announced that it has regained all rights to the

respiratory syncytial virus (RSV) vaccine (mRNA-1172) from Merck, known as MSD

outside the United States and Canada, including rights to develop RSV vaccines

for adult populations. mRNA-1172, which uses a Merck lipid nanoparticle for

delivery, entered Phase 1 development in 2019. Under the terms of the

agreement, Merck will complete the Phase 1 study and transition the program to

Moderna. Moderna has now consolidated all global commercial rights to all

development candidates in its core prophylactic vaccines modality. 

Global Respiratory Syncytial Virus(RSV) Therapeutics Market Split by Product Type and Applications:

Market Segment by Type, covers:

Palivizumab
Ribavirin
Others

Market Segment by Applications, covers:

Hospital Pharmacies
Drug Stores
Retail Pharmacies
Others

Regional Analysis For Respiratory Syncytial Virus(RSV) Therapeutics Market:

North America, Latin America, Asia-Pacific, Africa, and Europe and others have been studied at length based on various parameters of businesses such as type, size, application, and end-users.  The global Respiratory Syncytial Virus(RSV) Therapeutics Market is presented for niche reading. The report presents portfolios of different strategies and the best practices governing businesses. Some applicable sales methodologies have been included in this research report,  that could influence business output. 

Enquire For Discount:

https://www.marketinsightsreports.com/reports/05032856998/global-respiratory-syncytial-virus-rsv-therapeutics-market-2021-by-company-regions-type-and-application-forecast-to-2026/discount?Mode=G88

Major Points Covered in TOC:

Overview: Along with a broad overview of the global Respiratory Syncytial Virus(RSV) Therapeutics market, this section gives an overview of the report to give an idea about the nature and contents of the research study.

Analysis on Strategies of Leading Players: Market players can use this analysis to gain a competitive advantage over their competitors in the Respiratory Syncytial Virus(RSV) Therapeutics market.

Study on Key Market Trends: This section of the report offers a deeper analysis of the latest and future trends of the Respiratory Syncytial Virus(RSV) Therapeutics market.

Market Forecasts: Buyers of the report will have access to accurate and validated estimates of the total market size in terms of value and volume. The report also provides consumption, production, sales, and other forecasts for the Respiratory Syncytial Virus(RSV) Therapeutics market.

Regional Growth Analysis: All major regions and countries have been covered in the report. The regional analysis will help market players to tap into unexplored regional markets, prepare specific strategies for target regions, and compare the growth of all regional markets.

Market Analysis: The report provides accurate and reliable forecasts of the market share of important segments of the Respiratory Syncytial Virus(RSV) Therapeutics market. Market participants can use this analysis to make strategic investments in key growth pockets of the Respiratory Syncytial Virus(RSV) Therapeutics market.

Research Methodology:

Respiratory Syncytial Virus(RSV) Therapeutics Market report includes the estimation of market size for value (million USD) and volume (M Sqm). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Respiratory Syncytial Virus(RSV) Therapeutics Market, to estimate the size of various other dependent submarkets in the overall market.

Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage share, split, and breakdowns have been determined using secondary sources and verified primary sources.

To Browse Full Report:

https://www.marketinsightsreports.com/reports/05032856998/global-respiratory-syncytial-virus-rsv-therapeutics-market-2021-by-company-regions-type-and-application-forecast-to-2026?Mode=G88

How we have factored the effect of Covid-19 in our report:

All the reports that we list have been tracking the impact of COVID-19 the market. Both upstream and downstream of the entire supply chain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check with the sales team.

We also offer customization on reports based on specific client requirement:

1- Free Country level analysis for any 5 countries of your choice.

2- Free Competitive analysis of any 5 key market players.

3- Free 40 analyst hours to cover any other data points

Contact Us:

Irfan Tamboli (Head of Sales) – MarketInsightsReports

Phone: + 1704 266 3234 | +91-20-412 512 12

sales@marketinsightsreports.com | irfan@marketinsightsreports.com

ABOUT US:

MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Respiratory Syncytial Virus(RSV) Therapeutics Market Growth, New Updates, Trends, Analysis and Global Research Report 2021-2026 here

News-ID: 2293868 • Views: 769

More Releases from Marketinsightsreports

Floated House Market  2021 – Increasing Demand, Growth Analysis and Future Ou …
The report entitled, “Global Floated House Market” is a unique market study that offers the latest in-depth information and comprehensive analysis of the market. It provides a complete overview of the market with detailed insights on key aspects including the current market situation, potential size, volume, and dynamics of the market. This research report makes a thorough assessment of the COVID-19 pandemic and its impact on the current market and
Auto Halogen Lamp Market Growing Demand and Manufacturing Analysis 2021- 2027 | …
The report entitled, “Global Auto Halogen Lamp Market” is a unique market study that offers the latest in-depth information and comprehensive analysis of the market. It provides a complete overview of the market with detailed insights on key aspects including the current market situation, potential size, volume, and dynamics of the market. This research report makes a thorough assessment of the COVID-19 pandemic and its impact on the current market
Exhaust Gas Turbochargers Market 2021 Growth, Analysis and Advancement Outlook | …
The report entitled, “Global Exhaust Gas Turbochargers Market” is a unique market study that offers the latest in-depth information and comprehensive analysis of the market. It provides a complete overview of the market with detailed insights on key aspects including the current market situation, potential size, volume, and dynamics of the market. This research report makes a thorough assessment of the COVID-19 pandemic and its impact on the current market
Forestry Equipment Market Global Production, Demand and Business Outlook 2021 | …
The report entitled, “Global Forestry Equipment Market” is a unique market study that offers the latest in-depth information and comprehensive analysis of the market. It provides a complete overview of the market with detailed insights on key aspects including the current market situation, potential size, volume, and dynamics of the market. This research report makes a thorough assessment of the COVID-19 pandemic and its impact on the current market and

All 5 Releases


More Releases for RSV

RSV Diagnostics Market | Pin-Point Analysis for Changing Competitive Dynamics
Human respiratory syncytial virus (RSV) is a virus that commonly causes lower respiratory tract infection. Human respiratory syncytial virus infections are acquired during hospital visits. Infants and in young children are more prone to human respiratory syncytial virus (RSV) infection. RSV infections affect lungs and respiratory tract of an individual. In premature babies and children with previous presence of diseases, RSV infections affect heart and immune systems as well resulting
RSV Diagnostics Market Trend | Industry Analysis Report, 2019
Human respiratory syncytial virus (RSV) is a virus that commonly causes lower respiratory tract infection. Human respiratory syncytial virus infections are acquired during hospital visits. Infants and in young children are more prone to human respiratory syncytial virus (RSV) infection. RSV infections affect lungs and respiratory tract of an individual. In premature babies and children with previous presence of diseases, RSV infections affect heart and immune systems as well resulting
RSV Diagnostics Market Set to Surge Significantly During 2019
Human respiratory syncytial virus (RSV) is a virus that commonly causes lower respiratory tract infection. Human respiratory syncytial virus infections are acquired during hospital visits. Infants and in young children are more prone to human respiratory syncytial virus (RSV) infection. RSV infections affect lungs and respiratory tract of an individual. In premature babies and children with previous presence of diseases, RSV infections affect heart and immune systems as well resulting
Human Respiratory Syncytial Virus (RSV) Treatment Market Analysis, a Size and Fo …
A syncytial virus is a multi-nucleated virus which results from multiple cell fusions. Human respiratory syncytial virus (RSV) has a size of around 120 to 200 nm and is an enveloped virus with a linear minus-sense RNA genome. Human respiratory syncytial virus (RSV) causes complications such as bronchiolitis, asthma, chronic respiratory tract infections and acute otitis media in patients. Human respiratory syncytial virus (RSV) infects the lungs and breathing passages.
OpportunityAnalyzer: Respiratory Syncytial Virus (RSV) - Opportunity Analysis An …
Summary Human respiratory syncytial virus (RSV) is an enveloped, single-stranded, negative-sense ribonucleic acid (RNA) pneumovirus belonging to the family of Paramyxoviridae. The virus was discovered in 1956, first as an isolate from a laboratory chimpanzee displaying symptoms of the common cold, and later from infants suffering from respiratory disease. RSV can cause upper respiratory tract infections (the common cold) and is the most important cause of lower respiratory tract infections, such
Synagis (Pediatric RSV) - Forecast And Market Analysis To 2022
Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Synagis (Pediatric RSV) Forecast and Market Analysis to 2022. Respiratory syncytial virus (RSV) is a common cause of pediatric respiratory infections and virtually all children will have been infected by the virus by the age of two. RSV transmission typically occurs during the winter and early spring months. The virus is spread through the air by an infected persons sneeze or